Combined therapy with GnRH analog plus growth hormone in central precocious puberty.

Pucarelli I, Segni M, Ortore M, Moretti A, Iannaccone R, Pasquino AM

Journal of pediatric endocrinology & metabolism : JPEM1 Jul 2000Cited by 16 (Europe PMC)

PMID10969926DOI10.1515/jpem.2000.13.s1.811PepBankPUB-10969926

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialEfficacy outcome
In central precocious puberty, adult height after triptorelin alone did not significantly exceed pretreatment predicted height.
In plain wordsIn early puberty, adult height after triptorelin alone did not significantly exceed the initial prediction.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeAdult height versus initial prediction
Study
n = 10
Comparator
Pretreatment predicted adult height
Outcome group
Linear growth · Endocrine and hormones
Studied dose
100 microg/kg every 21 days · intramuscular · at least 2-3 yrAs given in this study (human).
Measurements
Adult height
157.1 cm
GnRH alone
Predicted adult height
155.5 cm
pretreatment
Source sentences
Summary
The GnRH alone treated group reached an adult height not significantly higher than pretreatment PAH (157.1 +/- 2.5 vs 155.5 +/- 1.9 cm).
2 context sentences(design, population, supporting numbers)
Summary · context
Of 20 patients with idiopathic CPP (treated with GnRHa [depot-triptorelin] at a dose of 100 microg/kg every 21 days i.m. for at least 2-3 yr)
Summary · context
Ten patients matched for BA, CA, and duration of GnRHa treatment who showed the same growth pattern but refused GH treatment, served to evaluate the efficacy of the addition of GH.
Report a problemFND-1096992604
02HumanNon-randomized trialEfficacy outcome
In central precocious puberty, height SDS for bone age did not change significantly with triptorelin alone.
In plain wordsIn early puberty, height relative to bone age did not change significantly with triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeHeight SDS for bone age
Study
n = 10
Outcome group
Linear growth · Endocrine and hormones
Studied dose
100 microg/kg every 21 days · intramuscular · at least 2-3 yrAs given in this study (human).
Measurements
Height SDS for bone age
−1 SDS
start of GnRHa, GnRHa alone group
Height SDS for bone age
−0.7 SDS
adult height, GnRHa alone group
Source sentences
Summary
Height SDS for BA did not change (from -1.0 +/- 0.3 at start of GnRHa to -0.7 +/- 0.4 at adult height).
3 context sentences(design, population, supporting numbers)
Summary · context
The GnRH alone treated group reached an adult height not significantly higher than pretreatment PAH (157.1 +/- 2.5 vs 155.5 +/- 1.9 cm).
Summary · context
Of 20 patients with idiopathic CPP (treated with GnRHa [depot-triptorelin] at a dose of 100 microg/kg every 21 days i.m. for at least 2-3 yr)
Summary · context
Ten patients matched for BA, CA, and duration of GnRHa treatment who showed the same growth pattern but refused GH treatment, served to evaluate the efficacy of the addition of GH.
Report a problemFND-1096992605
03HumanNon-randomized trialEfficacy outcome
In central precocious puberty, triptorelin alone reached but did not significantly exceed target height.
In plain wordsIn early puberty, adult height after triptorelin alone reached but did not significantly exceed target height.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeAdult height versus target
Study
n = 10
Comparator
Target height
Outcome group
Linear growth · Endocrine and hormones
Studied dose
100 microg/kg every 21 days · intramuscular · at least 2-3 yrAs given in this study (human).
Source sentences
Summary
Target height was just reached but not significantly exceeded.
3 context sentences(design, population, supporting numbers)
Summary · context
The GnRH alone treated group reached an adult height not significantly higher than pretreatment PAH (157.1 +/- 2.5 vs 155.5 +/- 1.9 cm).
Summary · context
Of 20 patients with idiopathic CPP (treated with GnRHa [depot-triptorelin] at a dose of 100 microg/kg every 21 days i.m. for at least 2-3 yr)
Summary · context
Ten patients matched for BA, CA, and duration of GnRHa treatment who showed the same growth pattern but refused GH treatment, served to evaluate the efficacy of the addition of GH.
Report a problemFND-1096992606

Studies that did not test the peptide alone7

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In central precocious puberty, height gain was greater with triptorelin plus growth hormone than with triptorelin alone.
In plain wordsIn early puberty, triptorelin plus growth hormone produced greater height gain than triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseHeight gain versus monotherapy
Study
n = 20
Comparator
Triptorelin alone
Outcome group
Linear growth · Endocrine and hormones
Measurements
Height gain
7.9 cm
GH combined with GnRH analogue
Height gain
1.6 cm
GnRH analogue alone
Source sentences
Summary
The gain in centimeters obtained calculated between pretreatment PAH and final height was 7.9 +/- 1.1 cm in patients treated with GH combined with GnRH analogue while in patients treated with GnRH analogue alone the gain was just 1.6 cm +/- 1.2 (p=0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
Of 20 patients with idiopathic CPP (treated with GnRHa [depot-triptorelin] at a dose of 100 microg/kg every 21 days i.m. for at least 2-3 yr)
Summary · context
Ten patients matched for BA, CA, and duration of GnRHa treatment who showed the same growth pattern but refused GH treatment, served to evaluate the efficacy of the addition of GH.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1096992607
05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In central precocious puberty, adult height after triptorelin plus growth hormone exceeded pretreatment predicted height.
In plain wordsIn early puberty, adult height after triptorelin plus growth hormone exceeded the initial prediction.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseAdult height versus initial prediction
Study
n = 10
Comparator
Pretreatment predicted adult height
Outcome group
Linear growth · Endocrine and hormones
Measurements
Adult height
160.6 cm
GH plus GnRHa
Predicted adult height
152.7 cm
pretreatment
Source sentences
Summary
Patients of the group treated with GH + GnRHa showed an adult height significantly higher (p<0.001) than pretreatment PAH (160.6 +/- 1.3 vs 152.7 +/- 1.7 cm).
2 context sentences(design, population, supporting numbers)
Summary · context
Of 20 patients with idiopathic CPP (treated with GnRHa [depot-triptorelin] at a dose of 100 microg/kg every 21 days i.m. for at least 2-3 yr)
Summary · context
Ten patients matched for BA, CA, and duration of GnRHa treatment who showed the same growth pattern but refused GH treatment, served to evaluate the efficacy of the addition of GH.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1096992601
06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In central precocious puberty, height SDS for bone age increased during triptorelin plus growth hormone treatment.
In plain wordsIn early puberty, height relative to bone age increased during triptorelin plus growth hormone treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseHeight SDS for bone age
Study
n = 10
Outcome group
Linear growth · Endocrine and hormones
Measurements
Height SDS for bone age
−1.5 SDS
start of GnRHa, GH plus GnRHa group
Height SDS for bone age
−0.21 SDS
adult height, GH plus GnRHa group
Source sentences
Summary
Height SDS for BA significantly increased from -1.5 +/- 0.2 at start of GnRHa to -0.21 +/- 0.2 at adult height (p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
Patients of the group treated with GH + GnRHa showed an adult height significantly higher (p<0.001) than pretreatment PAH (160.6 +/- 1.3 vs 152.7 +/- 1.7 cm).
Summary · context
Of 20 patients with idiopathic CPP (treated with GnRHa [depot-triptorelin] at a dose of 100 microg/kg every 21 days i.m. for at least 2-3 yr)
Summary · context
Ten patients matched for BA, CA, and duration of GnRHa treatment who showed the same growth pattern but refused GH treatment, served to evaluate the efficacy of the addition of GH.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1096992602
07HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In central precocious puberty, triptorelin plus growth hormone produced adult height significantly above target height.
In plain wordsIn early puberty, adult height after triptorelin plus growth hormone significantly exceeded target height.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseAdult height versus target
Study
n = 10
Comparator
Target height
Outcome group
Linear growth · Endocrine and hormones
Source sentences
Summary
Target height was significantly exceeded.
3 context sentences(design, population, supporting numbers)
Summary · context
Patients of the group treated with GH + GnRHa showed an adult height significantly higher (p<0.001) than pretreatment PAH (160.6 +/- 1.3 vs 152.7 +/- 1.7 cm).
Summary · context
Of 20 patients with idiopathic CPP (treated with GnRHa [depot-triptorelin] at a dose of 100 microg/kg every 21 days i.m. for at least 2-3 yr)
Summary · context
Ten patients matched for BA, CA, and duration of GnRHa treatment who showed the same growth pattern but refused GH treatment, served to evaluate the efficacy of the addition of GH.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1096992603
08HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialSafety outcome
No side effects occurred in patients with central precocious puberty receiving triptorelin plus growth hormone.
In plain wordsNo side effects occurred in patients receiving triptorelin plus growth hormone for early puberty.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableSide effects
Study
n = 10
Outcome group
Adverse events · Endocrine and hormones
Source sentences
Summary
Furthermore, no side effects, bone age progression, or ovarian cysts, were observed in GnRHa + GH treated patients.
2 context sentences(design, population, supporting numbers)
Summary · context
Of 20 patients with idiopathic CPP (treated with GnRHa [depot-triptorelin] at a dose of 100 microg/kg every 21 days i.m. for at least 2-3 yr)
Summary · context
Ten patients matched for BA, CA, and duration of GnRHa treatment who showed the same growth pattern but refused GH treatment, served to evaluate the efficacy of the addition of GH.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1096992608
09HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
No bone age progression occurred in patients with central precocious puberty receiving triptorelin plus growth hormone.
In plain wordsNo bone age progression occurred in patients receiving triptorelin plus growth hormone for early puberty.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableBone age progression
Study
n = 10
Outcome group
Linear growth · Endocrine and hormones
Source sentences
Summary
Furthermore, no side effects, bone age progression, or ovarian cysts, were observed in GnRHa + GH treated patients.
2 context sentences(design, population, supporting numbers)
Summary · context
Of 20 patients with idiopathic CPP (treated with GnRHa [depot-triptorelin] at a dose of 100 microg/kg every 21 days i.m. for at least 2-3 yr)
Summary · context
Ten patients matched for BA, CA, and duration of GnRHa treatment who showed the same growth pattern but refused GH treatment, served to evaluate the efficacy of the addition of GH.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1096992609
10HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialSafety outcome
No ovarian cysts occurred in patients with central precocious puberty receiving triptorelin plus growth hormone.
In plain wordsNo ovarian cysts occurred in patients receiving triptorelin plus growth hormone for early puberty.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableOvarian cysts
Study
n = 10
Outcome group
Adverse events · Endocrine and hormones
Source sentences
Summary
Furthermore, no side effects, bone age progression, or ovarian cysts, were observed in GnRHa + GH treated patients.
2 context sentences(design, population, supporting numbers)
Summary · context
Of 20 patients with idiopathic CPP (treated with GnRHa [depot-triptorelin] at a dose of 100 microg/kg every 21 days i.m. for at least 2-3 yr)
Summary · context
Ten patients matched for BA, CA, and duration of GnRHa treatment who showed the same growth pattern but refused GH treatment, served to evaluate the efficacy of the addition of GH.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1096992610

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.